STOCK TITAN
  1. Home
  2. Sec-filings
  3. INAB
  4. [EFFECT] IN8BIO, INC. SEC Filing

[EFFECT] IN8BIO, INC. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 28, 2026 4:00 P.M.
Form: S-3
CIK: 0001740279
Company Name: IN8BIO, INC.
File Number: 333-292830

Source: View Original Filing on SEC EDGAR

Stock INAB logo
In8Bio, Inc.

NASDAQ:INAB

INAB Rankings

#6052 Ranked by Market Cap
N/A Ranked by Dividends

INAB Latest News

Jan 12, 2026
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
Dec 19, 2025
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
Nov 6, 2025
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Oct 29, 2025
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
Oct 27, 2025
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

INAB Latest SEC Filings

Jan 30, 2026
[424B3] IN8BIO, INC. Prospectus Filed Pursuant to Rule 424(b)(3)
Jan 29, 2026
[SCHEDULE 13G] IN8BIO, INC. Passive Investment Disclosure (>5%)
Jan 20, 2026
[S-3] IN8BIO, INC. Shelf Registration Statement
Nov 24, 2025
[8-K] IN8BIO, INC. Reports Material Event
Nov 7, 2025
[S-3] IN8BIO, INC. Shelf Registration Statement

INAB Stock Data

19.53M
8.63M
5.56%
19.29%
1.01%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK